U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586215) titled 'HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity' on June 26, 2025.
Brief Summary: The study will be conducted as an open-label, single-center, Phase II clinical study, with a planned enrollment of 70 patients with locally advanced or metastatic HER2-positive and HER2-low breast cancer who are intended to receive at least two cycles of T-DXd monotherapy. All patients receiving T-DXd treatment must meet current clinical indications. After screening and enrollment, participants will undergo FDG-PET scans and free-of-charge HER2-PET scans prior to T-DXd treatment, with tissue biopsies performed as needed. Participants will rec...